OKUR
OnKure Therapeutics, Inc.
1W: +10.8%
1M: +58.7%
3M: +42.5%
YTD: +41.5%
1Y: -16.2%
3Y: -90.4%
$4.19
-0.19 (-4.34%)
After Hours: $4.47 (+0.28, +6.68%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$57.3M
52W Range1.7-5.1
Volume386,691
Avg Volume120,896
Beta0.46
Dividend—
Analyst Ratings
Company Info
CEONicholas A. Saccomano
Employees46
SectorHealthcare
IndustryBiotechnology
IPO Date2021-04-08
Websiteonkuretherapeutics.com
6707 Winchester Circle
Boulder, CO 80301
US
Boulder, CO 80301
US
720 307 2892
About OnKure Therapeutics, Inc.
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
Latest News
12 Health Care Stocks Moving In Thursday's After-Market Session
HC Wainwright Issues Positive Outlook for OKUR Earnings
OnKure Therapeutics GAAP EPS of -$0.09
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Analysts Set OnKure Therapeutics, Inc. (NASDAQ:OKUR) Target Price at $32.00
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Manke Isaac | A-Award | 5,258 | — | 2025-12-31 |
| Mathers Edward T | A-Award | 4,125 | — | 2025-09-30 |
| Manke Isaac | A-Award | 5,545 | — | 2025-09-30 |
| Saccomano Nicholas A | S-Sale | 88 | $2.62 | 2025-09-22 |
| Leverone Jason A. | S-Sale | 303 | $2.62 | 2025-09-22 |